Gastric Cancer Sentinel Lymph Node Mapping
Gastric Cancer, Sentinel Lymph Node, Early Gastric Cancer
About this trial
This is an interventional diagnostic trial for Gastric Cancer
Eligibility Criteria
Inclusion Criteria:
- All patients who are deemed healthy enough to withstand laparoscopic or open anatomic gastrectomy with extended regional (D2) lymphadenectomy will be eligible. Patients much have biopsy-proven, single lesion, <4cm gastric adenocarcinoma, of stage cT1/T2/T3 N0 M0.
Exclusion Criteria:
- Not able to withstand anatomical gastric resection with D2 lymphadenectomy, patient refusal, N+ve disease on pre-op work up, disease progression before surgery
Sites / Locations
- Montreal General HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Sentinel Node Sampling Arm
The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.